New Drugs for Difficult to Treat Cancers
Overview
Our research is focused on developing new drug paradigms to overcome clinical challenges in difficult to treat cancers. Namely tumor heterogeneity and an immunosuppressive tumor microenvironment. To achieve our goals a diversity of platforms are being investigated including:
Targeted delivery of therapeutic radiometals with immunostimulants
Antibody drug conjugates effective against quiescent cells
Biologic prodrugs to elicit immune cell penetration into solid tumors
